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Abstract
Background: Vascular cognitive impairment (VCI) is a heterogeneous entity with multiple aetiologies, all linked to
underlying vascular disease. Among these, VCI related to subcortical small vessel disease (SSVD) is emerging as a
major homogeneous subtype. Its progressive course raises the need for biomarker identification and/or
development for adequate therapeutic interventions to be tested. In order to shed light in the current status on
biochemical markers for VCI-SSVD, experts in field reviewed the recent evidence and literature data.
Method: The group conducted a comprehensive search on Medline, PubMed and Embase databases for studies
published until 15.01.2017. The proposal on current status of biochemical markers in VCI-SSVD was reviewed by all
co-authors and the draft was repeatedly circulated and discussed before it was finalized.
Results: This review identifies a large number of biochemical markers derived from CSF and blood. There is a
considerable overlap of VCI-SSVD clinical symptoms with those of Alzheimer’s disease (AD). Although most of the
published studies are small and their findings remain to be replicated in larger cohorts, several biomarkers have
shown promise in separating VCI-SSVD from AD. These promising biomarkers are closely linked to underlying SSVD
pathophysiology, namely disruption of blood-CSF and blood–brain barriers (BCB-BBB) and breakdown of white
matter myelinated fibres and extracellular matrix, as well as blood and brain inflammation. The leading
biomarker candidates are: elevated CSF/blood albumin ratio, which reflects BCB/BBB disruption; altered CSF
matrix metalloproteinases, reflecting extracellular matrix breakdown; CSF neurofilment as a marker of axonal
damage, and possibly blood inflammatory cytokines and adhesion molecules. The suggested SSVD biomarker
deviations contrasts the characteristic CSF profile in AD, i.e. depletion of amyloid beta peptide and increased
phosphorylated and total tau.
Conclusions: Combining SSVD and AD biomarkers may provide a powerful tool to identify with greater
precision appropriate patients for clinical trials of more homogeneous dementia populations. Thereby,
biomarkers might promote therapeutic progress not only in VCI-SSVD, but also in AD.
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Background
There are not yet efficient ways of treating or preventing
dementia disorders of which Alzheimer’s disease (AD)
remains the most common target for therapeutic inter-
ventions. In contrast, only few clinical pharmacological
trials have been conducted in subjects with vascular cog-
nitive impairment (VCI). The lack of treatment success
in VCI may be largely due to the heterogeneity of cere-
brovascular diseases, with the majority of VCI clinical
trials being performed in stroke patients. Only few
clinical trials have been performed in patients with sub-
cortical small vessel disease (SSVD), a common, fairly
homogeneous, but often under-recognized type of VCI
(VCI-SSVD) [1–4]. The clinical phenotype of combined
AD and vascular pathologies is often referred to as
mixed type dementia (MD). The overlap of SSVD, AD
and normal aging makes the underlying clinical diagno-
sis challenging, and it may lead to misclassification of
patients in treatment trials. One way of moving the field
forward is to be more specific about disease definitions
along the AD – SSVD axis. This, in turn, will allow for
refinements of diagnostic criteria with more sharply
defined patient cohorts.
Method
A focused meeting on VCI-SSVD biochemical markers
was held as a part of the 9th International Congress on
Vascular Dementia in Ljubljana, Slovenia, on 18 October,
2015. Experts in this field reviewed the current evidence
and literature data. For the purpose of this narrative re-
view, we conducted a comprehensive search on Medline,
PubMed and Embase databases for studies published until
15.01.2017. The key words used in the current search
were: subcortical small vessel disease, vascular dementia,
vascular cognitive impairment, Alzheimer’s disease, Bins-
wanger’s disease, biomarker(s), cerebrospinal fluid, blood,
serum, plasma, blood brain barrier, white matter, genetics,
tau protein(s), amyloid, inflammation. We critically
reviewed all abstracts and obtained the full text of relevant
papers. We grouped the identified relevant subcortical
small vessel disease biomarkers into themes and report
the major relevant findings. The proposal on current
status of biochemical markers in VCI-SSVD was reviewed
by the group, including additional experts who did not
attend the meeting. The draft was repeatedly circulated
and discussed before it was finalized.
Types of cerebral small vessel diseases, other vascular
lesions and Alzheimer pathology
Cerebral SSVD refers to pathological processes affecting
a spectrum of subcortical vascular changes visible on
Computed Tomography/Magnetic Resonance Imaging
(CT/MRI) as white matter lesions (WML), lacunes and
cerebral microbleeds. Underlying vascular pathologies
are arteriolosclerosis, lipohyalinosis, fibroid necrosis,
oedema and damage to the blood-cerebrospinal fluid
and blood–brain barriers (BCB/BBB), the latter resulting
in chronic leakage of fluid and macromolecules in the
white matter and inflammation (reviewed by Kalaria,
2016) [5]. Although SSVD pathogenesis remains poorly
understood, it is an age-related condition, associated
with a number of risk factors including systemic hyper-
tension [6–9], chronic kidney disease [10, 11], smoking
[12], metabolic syndrome [8, 13, 14], osteoporosis [15],
chronic obstructive pulmonary disease [16] and sleep-
apnoea syndrome [17]. The SSVD clinical manifestations
are largely due to complete (lacunes) or incomplete
(WML) infarction(s) and microbleeds resulting in cogni-
tive, motor and mood disturbances and eventually func-
tional disability [2], although same lesions might appear
in cognitively intact persons during normal ageing. In
patients with hypertension and WML, cerebral blood
flow autoregulation is restricted, resulting in lack of
physiological vasodilation during times of increased
oxygen and nutrient needs. This renders the brain
vulnerable to ischemic hypoperfusion, particularly in the
watershed regions of the white matter [18].
Clinico-pathological studies have associated the charac-
teristic clinical symptoms of VCI-SSVD (i.e. presence of
motor and executive slowing, forgetfulness and dysarthria)
with the bidirectional disruption of pathways connecting
the prefrontal cortex with the basal ganglia and thalamus
[2]. As opposed to other vascular subtypes, VCI-SSVD
patients presents with a slow progressive course, which
may mimic AD. On the other hand, late-onset AD
patients frequently have significant SSVD burden, not ne-
cessarily related to their amyloid load [19]. The disruption
of white matter network may be mediated via the effect of
the small vessel pathology, rather than amyloid deposits
[20]. A recent study showed age at onset as a crucial factor
that determines distinct features in subcortical VCI pa-
tients, such as pathologic burden, structural changes and
cognitive function. Early onset subcortical vascular cogni-
tive impairment was reported to be associated with more
lacunes, more severe frontal structural network disruption
and more affected frontal executive functions. In contrast,
later onset VCI-SSVD shows more pronounced amyloid
burden, cortical and hippocampal atrophy [21]. The
genetic component of VCI-SSVD is supported by the
presence of monogenic forms representing a small portion
of VCI-SSVD cases [22].
Biochemical markers
Although several studies using biochemical markers have
been completed and reviewed in AD, such information
is still lacking for VCI-SSVD. Here we review studies
using a broad range of biochemical markers from cere-
brospinal fluid (CSF), plasma or serum in VCI-SSVD.
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Our primary question is whether they are useful to
identify VCI-SSVD. We also review whether there are
overlapping and differentiating findings between VCI-
SSVD and AD.
Blood-CSF/blood–brain barriers (BCB/BBB)
The BCB/BBB are highly selective permeability barriers
that separate the circulating blood from the brain. The
function and structure of BCB/BBB alter with aging.
Disruption of BCB/BBB function, followed by blood-to-
brain extravasation of circulating neuroinflammatory
molecules, may increase the risk of brain injury. This
may be an important factor for disease progression in
both VCI and AD [23], and increasing evidence, also
from pre-clinical translational studies, indicates that dys-
function of the BCB/BBB may play a significant role in
the pathogenesis of vascular dementia [24–26]. The
CSF/serum albumin quotient (QA) is the gold-standard
measure of BCB/BBB integrity, with increases in this
ratio indicating increased permeability. QA requires the
measurement of albumin in CSF and serum collected con-
currently [27, 28]. Advancing age is associated with in-
creased BCB/BBB permeability, which is further increased
in patients with VCI (as compared to AD) and with wors-
ening of WML [29]. Altered BCB/BBB has consistently
been reported in VCI-SSVD patients, and it is thought to
contribute to the pathogenic process in AD [30–34].
Several lines of evidence suggested that the astrocytic
protein S100β is a potentially useful peripheral marker
of BCB/BBB permeability [35]. S100β can be released
from injured astrocytes and enter the extracellular space
and hence the bloodstream. This protein is elevated in
radiologically defined SSVD [36, 37]. A positive correl-
ation of S100β levels with the severity of depression, a
common symptom in SSVD, has also been reported [38].
Changes in BCB/BBB function correlate strongly with an
increase of two other proteins, namely glial fibrillary
acidic protein (GFAP) and neuron specific enolase (NSE)
in serum, indicating BCB/BBB leakage [39]. However,
they are both unspecific biological markers in dementia
disorders [40–42].
Inflammatory and glial activation markers
Both the innate immune system and systematic inflam-
mation have central roles in the pathophysiology of
cognitive impairment [43, 44]. While many molecules
within the inflammatory pathway are likely to be
involved, only few of them have been investigated in the
context of VCI-SSVD.
C reactive protein (CRP), a biomarker of systemic
inflammation, is perhaps the most extensively studied cir-
culatory biomarker of cerebral SSVD pathology. Although
its association with SSVD (particularly in the presence of
WML) is inconclusive [45–48], several studies have
suggested that elevated peripheral CRP level increases the
risk of VCI, but not AD [49, 50]. In addition, elevated
serum CRP appears to be consistently associated with
measures of white matter integrity [51, 52], whereas a
rapid decline in CRP levels predicts a healthier white mat-
ter microstructure [53].
Interleukins (ILs) are a group of cytokines participating
in the regulation of the immune response. A classification
that proves useful in clinical practice (outside of structural
biology) divides immunological cytokines into type 1
(IFN-γ, TNFα, TNFβ, IL-2, and IL-12-b), that enhances
cellular immune responses and type 2 (TGF-β, IL-4, IL-5,
IL-6, IL-10 and IL-13), which controls antibody responses.
In the vasculature, interleukin-6 (IL-6) is secreted as a
pro-inflammatory cytokine by tunica muscularis cells of
the blood vessels. As a response to IL-6, the liver synthe-
sizes the CRP. Although the majority of studies reported a
positive association [54], the usefulness of IL-6 and CRP as
biomarkers of SSVD, particularly in the presence of WML,
remains to be fully established [48]. In contrast, CSF TNF-
α, TGF-β and vascular endothelial growth factor (VEGF)
levels are all elevated in VCI-SSVD patients [55, 56].
CSF α1-antichymotrypsin, an acute phase inflamma-
tory protein, was also increased in individuals with VCI-
SSVD compared to healthy controls as well as in
prodromal VCI-SSVD patients who later progressed to
dementia, whereas in AD it was elevated only in mani-
fest dementia [57]. Interestingly, higher levels of serum
α1-antichymotrypsin in individuals with VCI, but not
AD, compared to controls have also been reported [58].
YKL-40, a marker of glial activation, was elevated in CSF
of patients with prodromal VCI but not prodromal AD [59].
Markers of extracellular matrix breakdown
Matrix metalloproteinases (MMPs) are a large family of
enzymes active in the extracellular matrix, at the cell
surface and intracellularly. Although there are 26 family
members, MMP-2, −3, −7, −9, −10 and −12 are mainly
active in the brain. Some MMPs, i.e. MMP-2, are constitu-
tively produced and are normally present in the CSF.
Others (mainly MMP-3 and MMP-9) are inducible with
very low levels in the CSF until an inflammatory response
is elicited [60, 61]. Changes in several MMPs have been
found in SSVD [33]. Measurement of MMPs and tissue
inhibitor of metalloproteinases-1 (TIMP-1) are promising
SSVD biomarkers, and have high validity in discriminating
VCI-SSVD from cognitive impairment of primarily neuro-
degenerative etiology [33, 34, 57, 62, 63].
Markers of subcortical neuronal degeneration and myelin
damage
Neurofilaments
Neurofilaments (NFs) are major structural proteins of
neurons. They consist of three subunits of low (NF-L),
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medium (NF-M), or high (NF-H) molecular weight with
varying degrees of phosphorylation [64]. NFs may be
sensitive surrogate markers for neuronal death and
axonal loss [65]. Several early studies detected NF
peptides in the CSF of several neurological/neurodegen-
erative disorders [66–69]. NF-L subunit is a protein
expressed in large-caliber myelinated axons [70]. Slightly
increased CSF NF-L levels occur in healthy older indi-
viduals and correlate with increasing age [66]. However,
a more significant increase in CSF NF-L levels is also
present in individuals with WML [32, 33, 71, 72]. A
positive association of CSF-NF-L levels with increasing
severity of WML in non-demented subjects has also
been reported [73].
In acute cerebral infarction, very high NF-L levels were
reported [66]. The CSF levels of NF-L were higher in
dementia disorders engaging subcortical brain regions,
such as VCI and MD, but also in fronto-temporal
dementia (FTD) [74, 75]. In VCI-SSVD the CSF NF-L
concentrations were consistently higher than in controls,
however with considerable overlap among other demen-
tia disorders [32, 72]. In a recent meta-analysis compar-
ing 106 VCI-SSVD patients with 283 healthy age-
matched controls, the patient group had increased CSF
NF-L levels. However, the overall elevation was smaller
than that for either AD or FTD patients versus controls
[76].
Increased WML load and ventricular dilation were
related to increased CSF levels of TIMP-1 and NF-L and
to decreased sAPPβ (a marker of amyloid pathology),
suggesting that these molecules may function as
biological markers of white matter damage [77].
Far less is known about CSF levels of the other NF
isoforms. One study reported increased CSF levels of
phosphorylated NF-H/M in AD compared with VCI and
controls [67]. Others have found elevated CSF NF-H
levels in AD and VCI in comparison with controls, but
no differences between FTD and controls, or between
AD, VCI and FTD patients [78].
Myelin basic protein
Myelin basic protein (MBP) is a major structural con-
stituent of the myelin sheath [79]. Its function is to
maintain the structure of the myelin and together with
myelin-associated glycoprotein (MAG) to modulate the
caliber of myelinated axons [80]. One of the hallmarks
of VCI-SSVD is the rarefaction of white matter, due to
nerve fiber degeneration, gliosis, demyelination or a
combination of all three [81, 82]. Significantly elevated
MBP CSF levels have been reported in stroke with sub-
cortical infarcts affecting the white matter, as opposed to
stroke with cortical infarcts [83], indicating its potential
as a regional marker of infarction, as well as a marker of
WML. Increased CSF levels of MBP and NF-L were
found in acute ischemic stroke patients. In mild stroke
{NIHSS <5 (National Institute of Health Stroke Scale)},
the concentration of MBP was significantly lower com-
pared to more severe stroke (NIHSS >5), while NF-L was
a stronger marker for stroke in general, independent of
severity [84]. Increased CSF levels of MBP and NF-L were
also described in patients with WML as compared to
controls. However, compared to controls, MBP and NF-L
were increased in both VCI-SSVD and AD patients, with
considerable overlap between patient groups [33].
CSF sulfatide
CSF sulfatide is an acidic glycophospholipid of
oligodendrocyte-produced myelin sheaths considered as
a marker of white matter degradation. It was found to
be 200% higher in patients with VCI-SSVD compared to
controls and patients with AD [85], while CSF sulfatide
levels distinguished between patients with subcortical ar-
teriosclerotic encephalopathy and those with normal
pressure hydrocephalus with a sensitivity and specificity
of 74 and 94% respectively [86]. CSF sulfatide has also
been shown to predict WML progression in nondisabled
patients with WML [87].
Furthermore, this marker was lower in mild cognitive
impairment and mild AD compared to control subjects
[88]. In another study TNF-α levels were significantly
correlated with sulfatide levels [89], suggesting that this
apoptosis-inducing cytokine may lead to oligodendro-
cytes death, thus contributing to white matter degener-
ation, a hallmark of SSVD.
Markers of cortical neuronal degeneration
Tau proteins
Tau protein is the major component of intracellularly lo-
cated neurofibrillary tangles and, in the neurofibrillary
pathology, it is present in a hyperphosphorylated form.
Both total and hyperphosphorylated tau have been found
to be increased in the CSF of patients with AD [90].
Total tau (T-tau) is viewed as a marker of neuronal and/
or axonal degeneration, while hyperphosphorylated tau
(P-tau) is a more specific marker of tangle formation in
AD [91]. Although their diagnostic accuracy may be re-
duced to variable degree when attempting differentiating
AD from other types of dementia, the above biomarkers,
especially when combined with Aβ42, achieve sensitiv-
ities and specificities >90% for the discrimination of AD
at least from normal ageing. They have now been incor-
porated in research guidelines for diagnosing incipient
and manifest AD [92, 93].
In VCI, CSF T-tau levels have been reported to be
either normal [94–96], increased [97–101], or intermedi-
ate between those found in controls and AD, but much
lower as compared to those of AD [102, 103]. Even then,
some patients with VCI do present with high or,
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sometimes, very high T-tau levels [96, 103–106]. When
patients with VCI, MD or AD with WML were clinically
separated, the results were again conflicting: T-tau in
VCI was reported as comparable to controls [96], in-
creased [101] or intermediate but much lower in
comparison to those of AD [103], while patients with
MD presented with increased T-tau in all studies. How-
ever, patients with lacunar infarcts [94], progressive
WML [99] or VCI-SSVD (pure and/or combined with
AD) [32, 33, 107, 108] had normal T-tau levels. The CSF
levels of P-tau have been described as normal in VCI or
VCI-SSVD [33, 100, 101, 103, 107, 108], while in MD,
levels were increased to the level of AD [103] or inter-
mediate between controls and AD [107].
Markers of amyloid pathology
β-amyloid
Beta-amyloid peptides with 40 (Aβ40) and, especially,
with 42 amino acids (Aβ42) are the major components
of extracellular AD amyloid plaques. Aβ42 is considered
to inversely reflect amyloid pathology, having high sensi-
tivity and specificity (>85%) as compared to cognitively
intact old subjects and is now recognized as one of the
three clinically useful CSF biomarkers (the other two
being T-tau and P-tau) for AD [28, 91]. Reduction of
CSF Aβ42 in VCI of any type [106] and VCI-SSVD with
or without signs of AD [33, 72, 108, 109], at levels simi-
lar to AD or intermediate between controls and AD have
been reported. In other studies, the levels of Aβ42 in
VCI were described as comparable to those of controls
and higher than in AD [95, 98, 100, 101, 103], although
overlap exists, with some VCI patients presenting with
low levels [103]. Most of the above studies agreed that
in MD, Aβ42 levels were reduced in a degree compar-
able to AD. However, the ratio of Aβ42/40, which is
reduced in AD, has been found to be comparable to
controls in “pure” VCI [110].
Amyloid precursor protein β
Soluble amyloid precursor protein β peptide (sAPPβ) is a
product of APP cleavage with potential neurotrophic
properties on axons [111]. CSF sAPPβ has been shown to
correlate with white matter lesion load in CSF [77] and
seems to be unaltered in the CSF in AD patients [112].
Markers of hypercoagulable state
Several plasma markers of coagulation/fibrinolysis have
been associated with VCI-SSVD [54]. The clotting cas-
cade is regulated by balance of activators and inhibitors.
Activators may be raised in hypercoagulable state either
independently or in parallel with the lowering of inhibi-
tors. The validation of candidate biomarkers is compli-
cated by the existence of heterogeneity among cerebral
vessels in different brain regions in response to
coagulation dysfunction [113]. In addition, a tenable as-
sociation with VCI-SSVD has often been difficult to
demonstrate with certainty for most proposed markers
[114]. Clinical observations have been strengthened, at
least in part, by a recent demonstration of a number of
downregulated coagulation-related genes in SSVD, after
postmortem gene-expression microarray analysis [115].
Markers of coagulation cascade
Fibrinogen is the endpoint plasma protein of the clot-
ting cascade. Conflicting results have been published
regarding its possible significance as a biomarker in
VCI-SSVD [116–122].
Factor VII (also known as serum prothrombin conver-
sion accelerator) has been found increased [123], whereas
antithrombin III, a plasma protein that inactivates throm-
bin, and D-dimer, a fibrin degradation product, were
found to be reduced in VCI-SSVD [113, 114, 124].
Markers derived from the endothelial cells, nearby tissue, or
platelets
Many studies report that numerous proteins expressed
by the endothelial cells are positively associated with la-
cunar infarcts or WML and thus increased in VCI-SSVD
because of endothelial damage [113, 123, 125–128].
There is a still growing list of these molecules, which in-
cludes: von Willebrand factor (vWF) [123]; thrombomo-
dulin (CD141 or BDCA-3); the monokine induced by γ-
interferon (MIG) or chemokine (C-X-C motif ) ligand 9
(CXCL-9) [129]; soluble intercellular adhesion molecule-
1 (sICAM-1 also known as CD54); soluble vascular cell
adhesion molecule-1 (sVCAM-1); and soluble E-selectin
(sE-selectin), the two latter mediating the adhesion of
white cells (except neutrophils) to the vascular endothe-
lium [130–133]. However, other neuropathology studies
did not confirm a local endothelial activation, and
showed that the endothelial layer remains intact in VCI-
SSVD [134, 135]. Specifically, the local expression of
ICAM-1 and thrombomodulin in the vascular endothe-
lium of small arteries was not confirmative of an associ-
ation with VCI-SSVD [136]. Thus, the usefulness of
these markers for diagnostic purposes remains to be
established, as recently reviewed [137].
Other neurotoxic/metabolic biomarkers
Homocysteine (Hcy) is the metabolic product of dietary
methionine. Hcy is also synthesized in the liver and kid-
ney. Increased total Hcy plasma levels is associated with
risk, clinical deterioration and severity of WML in symp-
tomatic patients with SSVD [138, 139]. Still, the links
between hyperhomocysteinemia and SSVD (including a
possible endothelial mechanism) are poorly understood
[138]. As recently reviewed, when Hcy plasma levels are
below 100 μM vascular effects are primarily seen,
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whereas adverse effects on the nerve cells appear, only
when concentrations exceed 100 μM (above clinically-
relevant range) [140]. Still we are far from a full identifi-
cation and characterization of the key molecular
pathways linking Hcy to VCI-SSVD. However, preclinical
and clinical data support the notion that Hcy is an
important mediator of VCI-SSVD.
B-type natriuretic peptide (BNP, also referred to as
ventricular natriuretic peptide) is a polypeptide secreted by
heart ventricles in response to excessive stretching of cardi-
omyocytes. Similarly, cardiac troponin T is a very sensitive
and specific indicator of myocardial damage. A few studies
report that serum levels of BNP [141, 142] or cardiac
troponin T [143] are elevated in VCI-SSVD. These results
need to be substantiated by other investigations to propose
these molecules as relevant biomarkers for VCI-SSVD.
Oxidative stress markers
Clinical studies on markers of oxidative stress in patients
with VCI-SSVD and cognitive impairment are scarce.
The Framingham study reported lower plasma levels of
myeloperoxidase in participants with greater WML vol-
umes and silent brain infarcts [47]. Asymmetric dimethy-
larginine (ADMA) is a key chemical involved in normal
endothelial function and thus cardiovascular health.
Higher plasma ADMA levels were associated with an in-
creased prevalence of silent brain infarcts after adjust-
ment for traditional stroke risk factors, indicating its
potential usefulness as a new biomarker of subclinical
vascular brain injury [144]. Patients with large-vessel dis-
ease had higher oxidative stress (as measured by the
serum levels of thiobarbituric acid-reactive substances),
but lower antioxidant defense (as measured by serum
levels of free thiol) compared to those with SSVD after
an acute ischemic stroke [145].
Results and discussion
Overlapping and differentiating biomarker findings in
VCI-SSVD and AD
Hitherto, there are no yet established biochemical markers
for VCI-SSVD, although there are potential candidates.
For AD, CSF T-tau, P-tau and Aβ42 have been included in
the diagnostic criteria by the National Institute on Aging
and the Alzheimer’s Association workgroup for all phases
of AD, published in 2011 [92]. By analogy, in VCI-SSVD a
major step forward will be to stratify biochemically
homogenous patient groups. From the evidence presented
in the current work, a significantly elevated albumin ratio
reflecting BCB/BBB dysfunction, a hallmark of VCI-SSVD,
is a consistent finding in studies with VCI-SSVD and MD
[32, 33, 146, 147]. In AD, the albumin ratio is not different
from that of controls [33, 72, 147, 148].
Other promising biomarkers are those reflecting damage
to the white matter, such as CSF NF-L and MBP. Both
markers correlate with SSVD, but they have also been
found to be elevated in AD. This overlap possibly reflects
concomitant AD and SSVD pathology. However, both CSF
NF-L and MBP can be of value in detecting damage to
white matter in patients with VCI-SSVD or MD regardless
of the white matter etiology. Markers, such as sulfatide,
sAPPβ, MMP-2, MMP-3, MMP-9 and TIMP-1, also hold
potential for VCI-SSVD biomarkers, though some of them
(MMP-2, MMP-3 and MMP-9) have also been described
to be altered in AD [33, 57, 62, 63, 77, 85–87, 149, 150].
Other glial and neuronal markers, such as YKL-40, GFAP,
S100B and NSE, are also related to AD and are thus not
specific [41, 42, 151–153]. Markers of inflammation (i.e.
IL-6, TNF-α, TGF-β, VEGF, sICAM-1, sVCAM and sE-
selectin) have all been found to be increased in both
diseases [56, 154, 155]. Other markers of questionable spe-
cificity for SSVD, as compared to AD, are CRP, ADMA
and Hcy, since they have also been found to be elevated in
AD [57, 155]. Biomarkers closely related to alterations of
the vessel wall (vWF, thrombomodulin) and partakers in
the coagulation/fibrinolysis system (D-dimer, Factor VII,
antithrombin III), rather than inflammation in general,
may prove to be more specific for VCI-SSVD and need to
be investigated in the context of AD differential diagnosis.
It should be noted that the overlap among the above-
mentioned biomarkers might be a result of heterogeneous
AD populations containing MD patients emphasizing the
need for further investigations of “pure” VCI-SSVD and
AD cases.
At present, combination of markers reflecting SSVD
with markers that seem to be more specific for AD path-
ology such as Aβ42, T-tau and especially P-tau, appears
promising for the exclusion of pure AD or favoring the
diagnosis of MD [33].
Are biomarkers useful for detection of VCI –SSVD in
clinical practice?
Thus far, biochemical markers with potential benefit for
the diagnosis of VCI-SSVD have limited use in every day
clinical practice (see Table 1). Since combination of bio-
markers increases accuracy of the AD diagnosis, it seems
feasible that a multimodal biomarker approach may be
beneficial for the diagnosis of VCI-SSVD as well. In the
Ten Point Scale of Binswanger’s disease (which is syn-
onymous with VCI-SSVD), three axes of biomarkers are
included: biochemical, imaging and clinical [34, 156].
Increased albumin ratio, reduced MMP-2, elevated
NF-L in the absence of a characteristic AD CSF pro-
file are emphasized as the most significant among
biochemical markers [34, 156]. Individuals with the
highest scores, i.e. presence of the most of the afore-
mentioned biomarkers, are most likely to have VCI-
SSVD. Of course, this scoring system requires
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Table 1 Summary of studies on candidate CSF biomarkers for VaD, VCI and SSVD according to their discrimination power (vs.
Controls and/or AD)
Candidate
biomarker
Study
[Ref]
Date Change HC
n
NC
n
VaD
n
VCI
n
SSVD
n
AD
n
Difference vs.
Controls
Difference
vs. AD
Sn/Sp vs.
Controls
Sn/Sp
vs. AD
Albumin ratio
(CSF/serum)
Wallin et al. [30] 1990 ↑ 30 - 53 - - - P < 0.001 - - -
Bjerke et al [72] 2009 → 52 - - - 9 20 NS NS - -
Bjerke et al. [33] 2011 ↑ 30 - - - 26 30 P < 0.005 P < 0.01 - -
Wallin et al. [32] 2001 ↑ 18 - - - 25 - P < 0.001 - - -
NSE Blennow et al. [41] 1994 ↑ 33 - 19 - - 45 P < 0.0001 NS - -
TNF-α Tarkowski et al. [55] 1999 ↑ 25 - 33 - - 34 P < 0.001 - - -
VEGF Tarkowski et al. [56] 2002 ↑ 27 - 26 - - 20 P = 0.03 NS - -
TGF-beta Tarkowski et al. [56] 2002 ↑ 27 - 26 - - 20 P < 0.0004 NS - -
YKL-40 Olsson et al. [59] 2013 ↑ - 65 19 - - - P < 0.05 - - -
MMP-9 Adair et al. [62] 2004 ↑ 8 - 15 - - 30 P < 0.003 P < 0.0001 - -
Bjerke et al. [33] 2011 ↑ 30 - - - 26 30 P < 0.05 P < 0.05 - -
MMP-10 Bjerke et al. [33] 2011 ↑ 30 - - - 26 30 P < 0.005 NS - -
MMP-2 Bjerke et al. [33] 2011 → 30 - - - 26 30 NS NS - -
MMP-3 Bjerke et al. [33] 2011 → 30 - - - 26 30 NS NS - -
TIMP-1 Ohrfelt et al. [57] 2011 ↑ 52 - - - 7 15 P = 0.01 - - -
Ohrfelt et al. [57] 2011 ↑ 52 - - - 8 24 P = 0.03 - - -
Bjerke et al. [33] 2011 ↑ 30 - - - 26 30 P < 0.05 P < 0.005 - -
TIMP-2 Bjerke et al. [33] 2011 → 30 - - - 26 30 NS NS - -
NF-L Wallin et al. [32] 2001 ↑ 18 - - - 25 - P < 0.001 - Sn 68%
Sp 85%
-
Bjerke et al. [72] 2009 ↑ 52 - - - 9 20 P < 0.001 NS - -
Bjerke et al. [33] 2011 ↑ 30 - - - 26 30 P < 0.0001 P < 0.05 - -
MBP Bjerke et al. [33] 2011 ↑ 30 - - - 26 30 P < 0.0001 P < 0.005 - -
Sulfatide Fredman et al. [85] 1992 ↑ 19 - 20 - - 43 P < 0.0001 P < 0.0001 - -
Total tau (τT) Wallin et al. [32] 2001 → 18 - - - 25 - NS - Sn 85%
Sp 36%
-
Paraskevas et al.
[103]
2009 ↑ 68 _- 23 -_ -_ 92 P < 0.05 P < 0.05 -_ Sn 80%
Sp 86%
Bjerke et al. [72] 2009 → 52 - - - 9 20 NS P < 0.005 - -
Bjerke et al. [33] 2011 ↑ 30 - - - 26 30 P < 0.005 NS - -
Phospho-tau
(τp-181)
Paraskevas et al.
[103]
2009 → 68 -_ 23 _- -_ 92 NS P < 0.01 -_ Sn 84%
Sp79%
Bjerke et al. [72] 2009 → 52 - - - 9 20 NS P < 0.005 - -
Bjerke et al. [33] 2011 → 30 - - - 26 30 NS P < 0.05 - -
Aβ42 Paraskevas et al.
[103]
2009 → 68 _- 23 -_ _- 92 NS NS -_ Sn 73%
Sp 70%
Bjerke et al. [72] 2009 ↓ 52 - - - 9 20 P < 0.05 P < 0.005 - -
Bjerke et al. [33] 2011 ↓ 30 - - - 26 30 P < 0.001 NS - -
Aβ42, τT, τp-181
(combination)
Paraskevas et al.
[103]
2009 ↑ 68 -_ 23 -_ _- 92 NS P < 0.01 _- Sn 87%
Sp 89%
sAPPβ Bjerke et al. [77] 2014 Correlation with
WML
- - -
VaD Vascular Dementia, VCI Vascular Cognitive Impairment, SSVD Subcortical Small Vessel Disease, AD Alzheimer’s disease, HC Healthy Controls, NC Neurological
Controls, Sn/Sp Sensitivity/Specificity, n number of controls/patients, ↓ reduced levels, ↑ increased levels, → no difference vs. controls, − not included, NS
Not Significant
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validation and standardization in large multi-centers
longitudinal studies.
Conclusion and future directions
VCI-SSVD is a common neurocognitive disorder with
similar clinical manifestations similar to other disorders,
such as AD. Underestimation of the impact of SSVD on
cognition and insufficient knowledge of SSVD in AD
may explain why VCI-SSVD is under-recognized in clin-
ical practice and not often studied in research contexts.
Biochemical markers may be of help for the (differential)
diagnosis of VCI-SSVD. They can also be used for iden-
tifying patients with preclinical SSVD from apparently
healthy controls. Furthermore, they have a potential to
define a spectrum disorder with pure subcortical vascu-
lar disease (i.e. Binswanger’s disease) at one end of the
spectrum and pure AD at the other. In between will be
the large group of MD patients that will remain a major
diagnostic challenge.
This review of all biological markers studied in pa-
tients with VCI-SSVD identified several fluid biomarkers
with evidence for use in diagnostic settings, while others
are too early to be considered as potential SSVD
biomarkers. There is little value of blood tests at this
time since none of the above biomarkers have been ad-
equately studied, whereas CSF helps to separate vascular
and neurodegenerative causes based on the presence of
BCB/BBB disruption and extracellular matrix break-
down. Obviously, many of the CSF reports cited in this
review are based on small series of cases. Replication
studies should be done to ensure the reproducibility of
the results and calculation of positive and negative
predictive values should be provided. At present, it is
unlikely that single markers may be sufficient for
diagnostic and differentiating purposes. Instead, a com-
bination of biochemical and imaging markers as well as
psychometrics will be necessary to improve the diagnos-
tic accuracy.
A third potential use of fluid biomarkers is their appli-
cation as surrogates for disease progression e.g. in
clinical pharmacological trials. For that purpose, such
biomarkers could be used if different levels of the
biomarkers can reflect patients’ clinical severity or extent
of WML. If a biomarker fulfills this definition, it could
be very valuable in clinical trials obviating the need for
repeated expensive MRI examinations.
A fourth potential use of fluid biomarkers is to clarify
the pathogenesis of the disorder, for example to verify an
inflammatory underlying process, perhaps in a subgroup
of patients, thus suggesting a (novel) target for therapy.
Clearly, much further work needs to be done along these
lines.
The search for an optimal panel of biomarkers with
high sensitivity and specificity through a collaborative
international network of biobanks, multi-center collec-
tions based on large patient cohorts, combined with
population genetics, clinical trials and harmonized pro-
tocols and procedures will provide the crucial tools
needed to enhance the likelihood of success in identify-
ing valid biomarkers in VCI-SSVD [157]. In addition,
research will benefit from innovative statistical ap-
proaches that allow handling large datasets, e.g. strat-
egies used in the field of artificial intelligence. With
combined efforts, the development of biomarkers in the
VCI-SSVD field may not only foster therapeutic progress
in VCI-SSVD but also in AD.
Abbreviations
AD: Alzheimer’s disease; ADMA: Asymmetric dimethylarginine; Aβ40: Beta-
amyloid peptide with 40 amino acids; Aβ42: Beta-amyloid peptide with 42
amino acids; BBB: Blood–brain barrier; BCB: Blood-cerebrospinal fluid barrier;
BNP: B-type natriuretic peptide; CRP: C reactive protein; CSF: Cerebrospinal
fluid; CT: Computed tomography; CXCL-9: Chemokine (C-X-C motif) ligand 9;
FTD: Fronto-temporal dementia; GFAP: Glial fibrillary acidic protein;
Hcy: Homocysteine; IL-6: Interleukin-6; ILs: Interleukins; MAG: Myelin-
associated glycoprotein; MBP: Myelin basic protein; MD: Mixed type
dementia; MIG: Monokine induced by γ-interferon; MMPs: Matrix
metalloproteinases; MRI: Magnetic resonance imaging; NF-H: Neurofilament
heavy subunit; NF-L: Neurolfilament light subunit; NF-M: Neurofilament
medium subunit; NFs: Neurofilaments; NIHSS: National institute of health
stroke scale; NSE: Neuron specific enolase; P-tau: Hyperphosphorylated tau;
QA: Cerebrospinal fluid/serum albumin quotient; sAPPβ: soluble amyloid
precursor protein β peptide; sE-selectin: soluble E-selectin; sICAM-1: soluble
intercellular adhesion molecule-1; SSVD: Subcortical small vessel disease;
sVCAM-1: soluble vascular cell adhesion molecule-1; TIMP-1: Tissue inhibitor
of metalloproteinases-1; T-tau: Total tau; VCI: Vascular cognitive impairment;
VCI-SSVD: Vascular cognitive impairment of the subcortical small vessel
disease type; WML: White matter lesions
Acknowledgements
We would like to thank Dr. Vasilios Constandinides for his contribution in the
preparation of the final version of the manuscript.
Funding
No funding was obtained for the preparation of the present manuscript.
Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated
during the current study.
Author’s contributions
AW and EK contributed substantially and equally to the conception and
design of the consensus report. Drafting and revising the manuscript
critically for intellectual content was jointly performed by AW, EK, MB, SE, DH,
BH, MJ, MK, LL, BM, SM, AM, EM-L, GP, BP, RR, LT, GT, GW, AK, MB and GR. All
authors approved the final version of the manuscript.
Competing interests
EBM-L - none, EK - none, GP – none, MGK – none, ADK – none, MB - none.
AW was consultant/speaker for Esai, Nutricia and received research funding
from Roche diagnostics. SE was/is consultant for and/or received research
funding from Janssen, ADxNeuroSciences, Innogenetics/Fujirebio Europe,
Lundbeck, Pfizer, Novartis, UCB, Roche diagnostics, Nutricia/Danone.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The article is based on original publications from ethically approved studies.
Wallin et al. BMC Neurology  (2017) 17:102 Page 8 of 12
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Psychiatry and Neurochemistry, Institute of Neuroscience
and Physiology, Sahlgrenska Academy at the University of Gothenburg,
Mölndal, Sweden. 21st Department of Neurology, Eginition Hospital, Medical
School, National and Kapodistrian University of Athens, Athens, Greece.
3Department of Neurology, University Hospital Centre Zagreb, Medical
School, University of Zagreb, Zagreb, Croatia. 4Memory Clinic and
Department of Neurology, Hospital Network Antwerp (ZNA) Middelheim and
HogeBeuken, Antwerp, Belgium. 5Reference Center for Biological Markers of
Dementia, Department of Biomedical Sciences, Institute Born-Bunge,
University of Antwerp, Antwerp, Belgium. 6Department of Neurology,
University Hospital Essen, Essen, Germany. 7Department of Neurology,
University of California, Irvine, California, USA. 8Department of Neurology,
University Medical Center Ljubljana, Ljubljana, Slovenia. 9Department of
Veterinary Sciences, University of Turin, Turin, Italy. 10Department of
Neurology, University Hospital “Alexandrovska”, Medical University, Sofia,
Bulgaria. 11Institute of Neuroscience, Campus for Ageing and Vitality,
Newcastle University, Newcastle upon Tyne NE4 5PL, UK. 12Department of
Neurology, Colentina Clinical Hospital, School of Medicine, ‘Carol Davila’
University of Medicine and Pharmacy, Bucharest, Romania. 13Brain Bank
Consultants, Amsterdam, The Netherlands. 142nd Department of Neurology,
Attikon Hospital, Medical School, National and Kapodistrian University of
Athens, Athens, Greece. 15School of Public Health, University of Haifa, Haifa,
Israel. 16Department of Neurology, Sackler School of Medicine, Tel Aviv
University, Tel Aviv, Israel. 17University of New Mexico Health Sciences Center,
Albuquerque, NM 87131, USA. 18Memory Clinic at Department of
Neuropsychiatry, Sahlgrenska University Hospital, Institute of Neuroscience
and Physiology at Sahlgrenska Academy, University of Gothenburg,
Wallinsgatan 6, SE-431 41 Mölndal, Sweden.
Received: 20 September 2016 Accepted: 9 May 2017
References
1. Erkinjuntti T. Diagnosis and management of vascular cognitive impairment
and dementia. J Neural Transm Suppl. 2002;63:91–109.
2. Roman GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC. Subcortical ischaemic
vascular dementia. Lancet Neurol. 2002;1(7):426–36.
3. Salvadori E, Poggesi A, Valenti R, Della Rocca E, Diciotti S, Mascalchi M, et al.
The rehabilitation of attention in patients with mild cognitive impairment
and brain subcortical vascular changes using the attention process training-
II. The RehAtt study: rationale, design and methodology. Neurol Sci. 2016;
37(10):1653–62.
4. Jia J, Wei C, Liang J, Zhou A, Zuo X, Song H, et al. The effects of DL-3-n-
butylphthalide in patients with vascular cognitive impairment without
dementia caused by subcortical ischemic small vessel disease: a multicentre,
randomized, double-blind, placebo-controlled trial. Alzheimers Dement.
2016;12(2):89–99.
5. Kalaria RN. Neuropathological diagnosis of vascular cognitive impairment
and vascular dementia with implications for Alzheimer's disease. Acta
Neuropathol. 2016;131(5):659–85.
6. de Leeuw FE, de Groot JC, Oudkerk M, Witteman JC, Hofman A, van Gijn J,
et al. Hypertension and cerebral white matter lesions in a prospective
cohort study. Brain. 2002;125(Pt 4):765–72.
7. Abraham HM, Wolfson L, Moscufo N, Guttmann CR, Kaplan RF, White WB.
Cardiovascular risk factors and small vessel disease of the brain: blood
pressure, white matter lesions, and functional decline in older persons.
J Cereb Blood Flow Metab. 2016;36(1):132–42.
8. Filomena J, Riba-Llena I, Vinyoles E, Tovar JL, Mundet X, Castane X, et al.
Short-term blood pressure variability relates to the presence of subclinical
brain small vessel disease in primary hypertension. Hypertension. 2015;66(3):
634–40. discussion 445
9. Pavlovic AM, Pekmezovic T, Zidverc Trajkovic J, Svabic Medjedovic T,
Veselinovic N, Radojicic A, et al. Baseline characteristic of patients presenting
with lacunar stroke and cerebral small vessel disease may predict future
development of depression. Int J Geriatr Psychiatry. 2016;31(1):58–65.
10. Toyoda G, Bokura H, Mitaki S, Onoda K, Oguro H, Nagai A, et al. Association
of mild kidney dysfunction with silent brain lesions in neurologically normal
subjects. Cerebrovasc Dis Extra. 2015;5(1):22–7.
11. Toyoda K. Cerebral small vessel disease and chronic kidney disease. J Stroke.
2015;17(1):31–7.
12. Staals J, Makin SD, Doubal FN, Dennis MS, Wardlaw JM. Stroke subtype,
vascular risk factors, and total MRI brain small-vessel disease burden.
Neurology. 2014;83(14):1228–34.
13. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes
mellitus and the risk of dementia: the Rotterdam study. Neurology. 1999;
53(9):1937–42.
14. Dearborn JL, Schneider AL, Sharrett AR, Mosley TH, Bezerra DC, Knopman
DS, et al. Obesity, insulin resistance, and incident small vessel disease on
magnetic resonance imaging: atherosclerosis risk in communities study.
Stroke. 2015;46(11):3131–6.
15. Alagiakrishnan K, Hsueh J, Zhang E, Khan K, Senthilselvan A. Small vessel
disease/white matter disease of the brain and its association with
osteoporosis. J Clin Med Res. 2015;7(5):297–302.
16. Lahousse L, Tiemeier H, Ikram MA, Brusselle GG. Chronic obstructive
pulmonary disease and cerebrovascular disease: a comprehensive review.
Respir Med. 2015;109(11):1371–80.
17. Durgan DJ, Bryan RM Jr. Cerebrovascular consequences of obstructive sleep
apnea. J Am Heart Assoc. 2012;1(4):e000091.
18. Makedonov I, Black SE, MacIntosh BJ. Cerebral small vessel disease in aging
and Alzheimer's disease: a comparative study using MRI and SPECT. Eur J
Neurol. 2013;20(2):243–50.
19. Ortner M, Kurz A, Alexopoulos P, Auer F, Diehl-Schmid J, Drzezga A, et al. Small
vessel disease, but neither amyloid load nor metabolic deficit, is dependent on
age at onset in Alzheimer's disease. Biol Psychiatry. 2015;77(8):704–10.
20. Kim HJ, Im K, Kwon H, Lee JM, Kim C, Kim YJ, et al. Clinical effect of white
matter network disruption related to amyloid and small vessel disease.
Neurology. 2015;85(1):63–70.
21. Jang YK, Kwon H, Kim YJ, Jung NY, Lee JS, Lee J, et al. Early- vs late-onset
subcortical vascular cognitive impairment. Neurology. 2016;86(6):527–34.
22. Bersano A, Debette S, Zanier ER, Lanfranconi S, De Simoni MG, Zuffardi O, et al.
The genetics of small-vessel disease. Curr Med Chem. 2012;19(24):4124–41.
23. Popescu BO, Toescu EC, Popescu LM, Bajenaru O, Muresanu DF, Schultzberg
M, et al. Blood–brain barrier alterations in ageing and dementia. J Neurol
Sci. 2009;283(1–2):99–106.
24. Ueno M, Chiba Y, Matsumoto K, Murakami R, Fujihara R, Kawauchi M, et al.
Blood–brain barrier damage in vascular dementia. Neuropathology. 2016;
36(2):115–24.
25. Srinivasan V, Braidy N, Chan EK, Xu YH, Chan DK. Genetic and environmental
factors in vascular dementia: an update of blood brain barrier dysfunction.
Clin Exp Pharmacol Physiol. 2016;43(5):515–21.
26. Wang M, Norman JE, Srinivasan VJ, Rutledge JC. Metabolic, inflammatory,
and microvascular determinants of white matter disease and cognitive
decline. Am J Neurodegener Dis. 2016;5(5):171-77.
27. Tibbling G, Link H, Ohman S. Principles of albumin and IgG analyses in
neurological disorders. I. Establishment of reference values. Scand J Clin Lab
Invest. 1977;37(5):385–90.
28. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and
plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131–44.
29. Farrall AJ, Wardlaw JM. Blood–brain barrier: ageing and microvascular disease–
systematic review and meta-analysis. Neurobiol Aging. 2009;30(3):337–52.
30. Wallin A, Blennow K, Fredman P, Gottfries CG, Karlsson I, Svennerholm L.
Blood brain barrier function in vascular dementia. Acta Neurol Scand. 1990;
81(4):318–22.
31. Wallin A, Sjogren M, Edman A, Blennow K, Regland B. Symptoms, vascular
risk factors and blood–brain barrier function in relation to CT white-matter
changes in dementia. Eur Neurol. 2000;44(4):229–35.
32. Wallin A, Sjogren M. Cerebrospinal fluid cytoskeleton proteins in patients with
subcortical white-matter dementia. Mech Ageing Dev. 2001;122(16):1937–49.
33. Bjerke M, Zetterberg H, Edman A, Blennow K, Wallin A, Andreasson U.
Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of
metalloproteinases in combination with subcortical and cortical biomarkers
in vascular dementia and Alzheimer's disease. J Alzheimers Dis. 2011;27(3):
665–76.
34. Rosenberg GA, Bjerke M, Wallin A. Multimodal markers of inflammation in
the subcortical ischemic vascular disease type of vascular cognitive
impairment. Stroke. 2014;45(5):1531–8.
Wallin et al. BMC Neurology  (2017) 17:102 Page 9 of 12
35. Marchi N, Cavaglia M, Fazio V, Bhudia S, Hallene K, Janigro D. Peripheral
markers of blood–brain barrier damage. Clin Chim Acta. 2004;342(1–2):
1–12.
36. Levada OA, Trailin AV. [Serum level of S100B as a marker of progression of
vascular mild cognitive impairment into subcortical vascular dementia and
therapy effectiveness]. Likars'ka sprava/Ministerstvo okhorony zdorov'ia
Ukrainy. 2012;2(3–4):53–59.
37. Gao Q, Fan Y, Mu LY, Ma L, Song ZQ, Zhang YN. S100B and ADMA in
cerebral small vessel disease and cognitive dysfunction. J Neurol Sci. 2015;
354(1–2):27–32.
38. Rothermundt M, Arolt V, Wiesmann M, Missler U, Peters M, Rudolf S, et al. S-
100B is increased in melancholic but not in non-melancholic major
depression. J Affect Disord. 2001;66(1):89–93.
39. Dittrich S, Sunyakumthorn P, Rattanavong S, Phetsouvanh R, Panyanivong P,
Sengduangphachanh A, et al. Blood–brain barrier function and biomarkers
of central nervous system injury in Rickettsial versus other neurological
infections in Laos. AmJTrop Med Hyg. 2015;93(2):232–7.
40. Mecocci P, Parnetti L, Romano G, Scarelli A, Chionne F, Cecchetti R, et al.
Serum anti-GFAP and anti-S100 autoantibodies in brain aging, Alzheimer's
disease and vascular dementia. J Neuroimmunol. 1995;57(1–2):165–70.
41. Blennow K, Wallin A, Ekman R. Neuron specific enolase in cerebrospinal
fluid: a biochemical marker for neuronal degeneration in dementia
disorders? J Neural Transm Park Dis Dement Sect. 1994;8(3):183–91.
42. Wallin A, Blennow K, Rosengren LE. Glial fibrillary acidic protein in the
cerebrospinal fluid of patients with dementia. Dementia. 1996;7(5):267–72.
43. Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer's disease.
Nat Immunol. 2015;16(3):229–36.
44. Holmes C. Review: systemic inflammation and Alzheimer's disease.
Neuropathol Appl Neurobiol. 2013;39(1):51–68.
45. Aribisala BS, Wiseman S, Morris Z, Valdes-Hernandez MC, Royle NA, Maniega
SM, et al. Circulating inflammatory markers are associated with magnetic
resonance imaging-visible perivascular spaces but not directly with white
matter hyperintensities. Stroke. 2014;45(2):605–7.
46. Satizabal CL, Zhu YC, Mazoyer B, Dufouil C, Tzourio C. Circulating IL-6 and
CRP are associated with MRI findings in the elderly: the 3C-Dijon study.
Neurology. 2012;78(10):720–7.
47. Shoamanesh A, Preis SR, Beiser AS, Vasan RS, Benjamin EJ, Kase CS, et al.
Inflammatory biomarkers, cerebral microbleeds, and small vessel disease:
Framingham heart study. Neurology. 2015;84(8):825–32.
48. van Dijk EJ, Prins ND, Vermeer SE, Vrooman HA, Hofman A, Koudstaal PJ, et
al. C-reactive protein and cerebral small-vessel disease: the Rotterdam scan
study. Circulation. 2005;112(6):900–5.
49. Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC,
et al. Inflammatory proteins in plasma and the risk of dementia: the
rotterdam study. Arch Neurol. 2004;61(5):668–72.
50. Ravaglia G, Forti P, Maioli F, Chiappelli M, Montesi F, Tumini E, et al. Blood
inflammatory markers and risk of dementia: the Conselice study of brain
aging. Neurobiol Aging. 2007;28(12):1810–20.
51. Miralbell J, Soriano JJ, Spulber G, Lopez-Cancio E, Arenillas JF, Bargallo N, et
al. Structural brain changes and cognition in relation to markers of vascular
dysfunction. Neurobiol Aging. 2012;33(5):1003.e1009–17.
52. Wersching H, Duning T, Lohmann H, Mohammadi S, Stehling C, Fobker M,
et al. Serum C-reactive protein is linked to cerebral microstructural integrity
and cognitive function. Neurology. 2010;74(13):1022–9.
53. Bettcher BM, Yaffe K, Boudreau RM, Neuhaus J, Aizenstein H, Ding J, et al.
Declines in inflammation predict greater white matter microstructure in
older adults. Neurobiol Aging. 2015;36(2):948–54.
54. Vilar-Bergua A, Riba-Llena I, Nafria C, Bustamante A, Llombart V, Delgado P,
et al. Blood and CSF biomarkers in brain subcortical ischemic vascular
disease: involved pathways and clinical applicability. J Cereb Blood Flow
Metab. 2016;36(1):55–71.
55. Tarkowski E, Blennow K, Wallin A, Tarkowski A. Intracerebral production of
tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer
disease and vascular dementia. J Clin Immunol. 1999;19(4):223–30.
56. Tarkowski E, Issa R, Sjogren M, Wallin A, Blennow K, Tarkowski A, et al.
Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in
Alzheimer's disease and vascular dementia. Neurobiol Aging. 2002;23(2):
237–43.
57. Ohrfelt A, Andreasson U, Simon A, Zetterberg H, Edman A, Potter W, et al.
Screening for new biomarkers for subcortical vascular dementia and
Alzheimer's disease. Dement Geriatr Cogn Dis Extra. 2011;1(1):31–42.
58. Ozturk C, Ozge A, Yalin OO, Yilmaz IA, Delialioglu N, Yildiz C. Tet al. The
diagnostic role of serum inflammatory and soluble proteins on dementia
subtypes: correlation with cognitive and functional decline. Behav Neurol.
2007;18(4):207–15.
59. Olsson B, Hertze J, Lautner R, Zetterberg H, Nagga K, Hoglund K, et al.
Microglial markers are elevated in the prodromal phase of Alzheimer's
disease and vascular dementia. J Alzheimers Dis. 2013;33(1):45–53.
60. Weekman EM, Wilcock DM. Matrix metalloproteinase in blood–brain barrier
breakdown in dementia. J Alzheimers Dis. 2016;49(4):893–903.
61. Rosenberg GA. Matrix metalloproteinase-mediated Neuroinflammation in
vascular cognitive impairment of the Binswanger type. Cell Mol Neurobiol.
2016;36(2):195–202.
62. Adair JC, Charlie J, Dencoff JE, Kaye JA, Quinn JF, Camicioli RM, et al.
Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of
patients with vascular dementia and Alzheimer disease. Stroke. 2004;
35(6):e159–62.
63. Candelario-Jalil E, Thompson J, Taheri S, Grossetete M, Adair JC, Edmonds E, et
al. Matrix metalloproteinases are associated with increased blood–brain barrier
opening in vascular cognitive impairment. Stroke. 2011;42(5):1345–50.
64. Hoffman PN, Cleveland DW, Griffin JW, Landes PW, Cowan NJ, Price DL.
Neurofilament gene expression: a major determinant of axonal caliber. Proc
Natl Acad Sci U S A. 1987;84(10):3472–6.
65. Perrot R, Berges R, Bocquet A, Eyer J. Review of the multiple aspects of
neurofilament functions, and their possible contribution to
neurodegeneration. Mol Neurobiol. 2008;38(1):27–65.
66. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with
amyotrophic lateral sclerosis and other neurodegenerative diseases have
increased levels of neurofilament protein in CSF. J Neurochem. 1996;67(5):
2013–8.
67. Hu YY, He SS, Wang XC, Duan QH, Khatoon S, Iqbal K, et al. Elevated levels
of phosphorylated neurofilament proteins in cerebrospinal fluid of
Alzheimer disease patients. Neurosci Lett. 2002;320(3):156–60.
68. Norgren N, Karlsson JE, Rosengren L, Stigbrand T. Monoclonal antibodies
selective for low molecular weight neurofilaments. Hybrid Hybridomics.
2002;21(1):53–9.
69. Gresle MM, Butzkueven H, Shaw G. Neurofilament proteins as body fluid
biomarkers of neurodegeneration in multiple sclerosis. Mult Scler Int. 2011;
2011:315406.
70. Friede RL, Samorajski T. Axon caliber related to neurofilaments and
microtubules in sciatic nerve fibers of rats and mice. Anat Rec. 1970;167(4):
379–87.
71. Sjogren M, Blomberg M, Jonsson M, Wahlund LO, Edman A, Lind K, et al.
Neurofilament protein in cerebrospinal fluid: a marker of white matter
changes. J Neurosci Res. 2001;66(3):510–6.
72. Bjerke M, Andreasson U, Rolstad S, Nordlund A, Lind K, Zetterberg H, et al.
Subcortical vascular dementia biomarker pattern in mild cognitive
impairment. Dement Geriatr Cogn Disord. 2009;28(4):348–56.
73. Jonsson M, Zetterberg H, van Straaten E, Lind K, Syversen S, Edman A, et al.
Cerebrospinal fluid biomarkers of white matter lesions - cross-sectional
results from the LADIS study. Eur J Neurol. 2010;17(3):377–82.
74. Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in
neurological diseases. Brain Res. 2003;987(1):25–31.
75. Skillback T, Farahmand B, Bartlett JW, Rosen C, Mattsson N, Nagga K, et al.
CSF neurofilament light differs in neurodegenerative diseases and predicts
severity and survival. Neurology. 2014;83(21):1945–53.
76. Petzold A, Keir G, Warren J, Fox N, Rossor MN. A systematic review and
meta-analysis of CSF neurofilament protein levels as biomarkers in
dementia. Neurodegener Dis. 2007;4(2–3):185–94.
77. Bjerke M, Jonsson M, Nordlund A, Eckerstrom C, Blennow K, Zetterberg H, et
al. Cerebrovascular biomarker profile is related to white matter disease and
ventricular dilation in a LADIS Substudy. Dement Geriatr Cogn Dis Extra.
2014;4(3):385–94.
78. Brettschneider J, Petzold A, Schottle D, Claus A, Riepe M, Tumani H. The
neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of
Alzheimer's disease. Dement Geriatr Cogn Disord. 2006;21(5–6):291–5.
79. Omlin FX, Webster HD, Palkovits CG, Cohen SR. Immunocytochemical
localization of basic protein in major dense line regions of central and
peripheral myelin. J Cell Biol. 1982;95(1):242–8.
80. Yin X, Crawford TO, Griffin JW, Tu P, Lee VM, Li C, et al. Myelin-associated
glycoprotein is a myelin signal that modulates the caliber of myelinated
axons. J Neurosci. 1998;18(6):1953–62.
Wallin et al. BMC Neurology  (2017) 17:102 Page 10 of 12
81. Wallin A, Blennow K, Uhlemann C, Langstrom G, Gottfries CG. White matter
low attenuation on computed tomography in Alzheimer's disease and
vascular dementia–diagnostic and pathogenetic aspects. Acta Neurol Scand.
1989;80(6):518–23.
82. Kalaria RN, Erkinjuntti T. Small vessel disease and subcortical vascular
dementia. J Clin Neurol. 2006;2(1):1–11.
83. Brouns R, De Vil B, Cras P, De Surgeloose D, Marien P, De Deyn PP.
Neurobiochemical markers of brain damage in cerebrospinal fluid of acute
ischemic stroke patients. Clin Chem. 2010;56(3):451–8.
84. Hjalmarsson C, Bjerke M, Andersson B, Blennow K, Zetterberg H, Aberg ND,
et al. Neuronal and glia-related biomarkers in cerebrospinal fluid of patients
with acute ischemic stroke. J Cent Nerv Syst Dis. 2014;6:51–8.
85. Fredman P, Wallin A, Blennow K, Davidsson P, Gottfries CG, Svennerholm L.
Sulfatide as a biochemical marker in cerebrospinal fluid of patients with
vascular dementia. Acta Neurol Scand. 1992;85(2):103–6.
86. Tullberg M, Mansson JE, Fredman P, Lekman A, Blennow K, Ekman R, et al.
CSF sulfatide distinguishes between normal pressure hydrocephalus and
subcortical arteriosclerotic encephalopathy. J Neurol Neurosurg Psychiatry.
2000;69(1):74–81.
87. Jonsson M, Zetterberg H, Rolstad S, Edman A, Gouw AA, Bjerke M, et al.
Low cerebrospinal fluid sulfatide predicts progression of white matter
lesions: the LADIS study. Dement Geriatr Cogn Disord. 2012;34(1):61–7.
88. Han X, Fagan AM, Cheng H, Morris JC, Xiong C, Holtzman DM.
Cerebrospinal fluid sulfatide is decreased in subjects with incipient
dementia. Ann Neurol. 2003;54(1):115–9.
89. Tarkowski E, Tullberg M, Fredman P, Wikkelso C. Correlation between
intrathecal sulfatide and TNF-alpha levels in patients with vascular
dementia. Dement Geriatr Cogn Disord. 2003;15(4):207–11.
90. Zetterberg H, Lautner R, Skillback T, Rosen C, Shahim P, Mattsson N, et al.
CSF in Alzheimer's disease. Adv Clin Chem. 2014;65:143–72.
91. Cavedo E, Lista S, Khachaturian Z, Aisen P, Amouyel P, Herholz K, et al. The
road ahead to cure Alzheimer's disease: development of biological markers
and Neuroimaging methods for prevention trials across all stages and
target populations. J Prev Alzheimers Dis. 2014;1(3):181–202.
92. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH,
et al. The diagnosis of dementia due to Alzheimer's disease:
recommendations from the National Institute on Aging-Alzheimer's
Association workgroups on diagnostic guidelines for Alzheimer's disease.
Alzheimers Dement. 2011;7(3):263–9.
93. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al.
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2
criteria. Lancet Neurol. 2014;13(6):614–29.
94. Mori H, Hosoda K, Matsubara E, Nakamoto T, Furiya Y, Endoh R, et al. Tau in
cerebrospinal fluids: establishment of the sandwich ELISA with antibody
specific to the repeat sequence in tau. Neurosci Lett. 1995;186(2–3):181–3.
95. Kapaki E, Paraskevas GP, Zalonis I, Zournas C. CSF tau protein and beta-
amyloid (1–42) in Alzheimer's disease diagnosis: discrimination from normal
ageing and other dementias in the Greek population. Eur J Neurol. 2003;
10(2):119–28.
96. Paraskevas GP, Kapaki E, Liappas I, Theotoka I, Mamali I, Zournas C, et al. The
diagnostic value of cerebrospinal fluid tau protein in dementing and nondementing
neuropsychiatric disorders. J Geriatr Psychiatry Neurol. 2005;18(3):163–73.
97. Tato RE, Frank A, Hernanz A. Tau protein concentrations in cerebrospinal
fluid of patients with dementia of the Alzheimer type. J Neurol Neurosurg
Psychiatry. 1995;59(3):280–3.
98. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H,
Winblad B, et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers
for Alzheimer disease in clinical practice. Arch Neurol. 2001;58(3):373–9.
99. Andreasen N, Vanmechelen E, Van de Voorde A, Davidsson P, Hesse C,
Tarvonen S, et al. Cerebrospinal fluid tau protein as a biochemical marker
for Alzheimer's disease: a community based follow up study. J Neurol
Neurosurg Psychiatry. 1998;64(3):298–305.
100. Jia JP, Meng R, Sun YX, Sun WJ, Ji XM, Jia LF. Cerebrospinal fluid tau,
Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease
and vascular dementia. Neurosci Lett. 2005;383(1–2):12–6.
101. Stefani A, Bernardini S, Panella M, Pierantozzi M, Nuccetelli M, Koch G, et al.
AD with subcortical white matter lesions and vascular dementia: CSF
markers for differential diagnosis. J Neurol Sci. 2005;237(1–2):83–8.
102. Leszek J, Malyszczak K, Janicka B, Kiejna A, Wiak A. Total tau in cerebrospinal
fluid differentiates Alzheimer's disease from vascular dementia. Med Sci
Monit. 2003;9(11):CR484–8.
103. Paraskevas GP, Kapaki E, Papageorgiou SG, Kalfakis N, Andreadou E, Zalonis I,
et al. CSF biomarker profile and diagnostic value in vascular dementia. Eur J
Neurol. 2009;16(2):205–11.
104. Vandermeeren M, Mercken M, Vanmechelen E, Six J, van de Voorde A,
Martin JJ, et al. Detection of tau proteins in normal and Alzheimer's disease
cerebrospinal fluid with a sensitive sandwich enzyme-linked
immunosorbent assay. J Neurochem. 1993;61(5):1828–34.
105. Vigo-Pelfrey C, Seubert P, Barbour R, Blomquist C, Lee M, Lee D, et al.
Elevation of microtubule-associated protein tau in the cerebrospinal fluid of
patients with Alzheimer's disease. Neurology. 1995;45(4):788–93.
106. Kaerst L, Kuhlmann A, Wedekind D, Stoeck K, Lange P, Zerr I. Cerebrospinal
fluid biomarkers in Alzheimer's disease, vascular dementia and ischemic
stroke patients: a critical analysis. J Neurol. 2013;260(11):2722–7.
107. Hermann P, Romero C, Schmidt C, Reis C, Zerr I. CSF biomarkers and
neuropsychological profiles in patients with cerebral small-vessel disease.
PLoS One. 2014;9(8):e105000.
108. Wallin A, Nordlund A, Jonsson M, Blennow K, Zetterberg H, Ohrfelt A, et al.
Alzheimer's disease-subcortical vascular disease spectrum in a hospital-
based setting: overview of results from the Gothenburg MCI and dementia
studies. J Cereb Blood Flow Metab. 2016;36(1):95–113.
109. Rosenberg GA, Prestopnik J, Adair JC, Huisa BN, Knoefel J, Caprihan A, et al.
Validation of biomarkers in subcortical ischaemic vascular disease of the
Binswanger type: approach to targeted treatment trials. J Neurol Neurosurg
Psychiatry. 2015;86(12):1324–30.
110. Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, et al.
Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42,
Abeta42/Abeta40 ratio and total tau. Neurobiol Aging. 2004;25(3):273–81.
111. Chasseigneaux S, Allinquant B. Functions of Abeta, sAPPalpha and sAPPbeta
: similarities and differences. J Neurochem. 2012;120(Suppl 1):99–108.
112. Rosen C, Andreasson U, Mattsson N, Marcusson J, Minthon L, Andreasen N,
et al. Cerebrospinal fluid profiles of amyloid beta-related biomarkers in
Alzheimer's disease. NeuroMolecular Med. 2012;14(1):65–73.
113. Kohriyama T, Yamaguchi S, Tanaka E, Yamamura Y, Nakamura S. Coagulation and
fibrinolytic parameters as predictors for small-vessel disease revealed by magnetic
resonance imaging of the brain. Rinsho Shinkeigaku. 1996;36(5):640–7.
114. Wiseman S, Marlborough F, Doubal F, Webb DJ, Wardlaw J. Blood markers
of coagulation, fibrinolysis, endothelial dysfunction and inflammation in
lacunar stroke versus non-lacunar stroke and non-stroke: systematic review
and meta-analysis. Cerebrovasc Dis. 2014;37(1):64–75.
115. Ritz MF, Grond-Ginsbach C, Kloss M, Tolnay M, Fluri F, Bonati LH, et al.
Identification of inflammatory, metabolic, and cell survival pathways
contributing to cerebral small vessel disease by postmortem gene
expression microarray. Curr Neurovasc Res. 2016;13(1):58–67.
116. Kilpatrick TJ, Matkovic Z, Davis SM, McGrath CM, Dauer RJ. Hematologic
abnormalities occur in both cortical and lacunar infarction. Stroke. 1993;
24(12):1945–50.
117. Bath PM, Blann A, Smith N, Butterworth RJ. Von Willebrand factor, P-selectin
and fibrinogen levels in patients with acute ischaemic and haemorrhagic
stroke, and their relationship with stroke sub-type and functional outcome.
Platelets. 1998;9(3–4):155–9.
118. Salobir B, Sabovic M, Peternel P, Stegnar M, Grad A. Classic risk factors,
hypercoagulability and migraine in young women with cerebral lacunar
infarctions. Acta Neurol Scand. 2002;105(3):189–95.
119. Jood K, Danielson J, Ladenvall C, Blomstrand C, Jern C. Fibrinogen gene
variation and ischemic stroke. J Thromb Haemost. 2008;6(6):897–904.
120. Alvarez-Perez FJ, Castelo-Branco M, Alvarez-Sabin J. Usefulness of measurement
of fibrinogen, D-dimer, D-dimer/fibrinogen ratio, C reactive protein and
erythrocyte sedimentation rate to assess the pathophysiology and mechanism
of ischaemic stroke. J Neurol Neurosurg Psychiatry. 2011;82(9):986–92.
121. Beer C, Blacker D, Hankey GJ, Puddey IB. Association of clinical and
aetiologic subtype of acute ischaemic stroke with inflammation, oxidative
stress and vascular function: a cross-sectional observational study. Med Sci
Monit. 2011;17(9):CR467–73.
122. Zhang B, Zhang W, Li X, Pu S, Yin J, Yang N, et al. Admission markers
predict lacunar and non-lacunar stroke in young patients. Thromb Res.
2011;128(1):14–7.
123. Vischer UM. Von Willebrand factor, endothelial dysfunction, and
cardiovascular disease. J Thromb Haemost. 2006;4(6):1186–93.
124. Isenegger J, Meier N, Lammle B, Alberio L, Fischer U, Nedeltchev K, et al. D-
dimers predict stroke subtype when assessed early. Cerebrovasc Dis. 2010;
29(1):82–6.
Wallin et al. BMC Neurology  (2017) 17:102 Page 11 of 12
125. Kario K, Matsuo T, Kobayashi H, Hoshide S, Shimada K. Hyperinsulinemia and
hemostatic abnormalities are associated with silent lacunar cerebral infarcts
in elderly hypertensive subjects. J Am Coll Cardiol. 2001;37(3):871–7.
126. Kearney-Schwartz A, Rossignol P, Bracard S, Felblinger J, Fay R, Boivin JM, et
al. Vascular structure and function is correlated to cognitive performance
and white matter hyperintensities in older hypertensive patients with
subjective memory complaints. Stroke. 2009;40(4):1229–36.
127. Nagai M, Hoshide S, Kario K. Association of prothrombotic status with
markers of cerebral small vessel disease in elderly hypertensive patients. Am
J Hypertens. 2012;25(10):1088–94.
128. Colombatti R, De Bon E, Bertomoro A, Casonato A, Pontara E, Omenetto E,
et al. Coagulation activation in children with sickle cell disease is associated
with cerebral small vessel vasculopathy. PLoS One. 2013;8(10):e78801.
129. Salmaggi A, Gelati M, Dufour A, Corsini E, Pagano S, Baccalini R, et al.
Expression and modulation of IFN-gamma-inducible chemokines (IP-10,
Mig, and I-TAC) in human brain endothelium and astrocytes: possible
relevance for the immune invasion of the central nervous system and the
pathogenesis of multiple sclerosis. J Interf Cytokine Res. 2002;22(6):631–40.
130. de Leeuw FE, de Kleine M, Frijns CJ, Fijnheer R, van Gijn J, Kappelle LJ.
Endothelial cell activation is associated with cerebral white matter lesions in
patients with cerebrovascular disease. Ann N Y Acad Sci. 2002;977:306–14.
131. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction:
testing and clinical relevance. Circulation. 2007;115(10):1285–95.
132. Han JH, Wong KS, Wang YY, Fu JH, Ding D, Hong Z. Plasma level of sICAM-1
is associated with the extent of white matter lesion among asymptomatic
elderly subjects. Clin Neurol Neurosurg. 2009;111(10):847–51.
133. Rouhl RP, Damoiseaux JG, Lodder J, Theunissen RO, Knottnerus IL, Staals J,
et al. Vascular inflammation in cerebral small vessel disease. Neurobiol
Aging. 2012;33(8):1800–6.
134. Craggs LJ, Hagel C, Kuhlenbaeumer G, Borjesson-Hanson A, Andersen O,
Viitanen M, et al. Quantitative vascular pathology and phenotyping familial
and sporadic cerebral small vessel diseases. Brain Pathol. 2013;23(5):547–57.
135. Lammie GA. Hypertensive cerebral small vessel disease and stroke. Brain
Pathol. 2002;12(3):358–70.
136. Giwa MO, Williams J, Elderfield K, Jiwa NS, Bridges LR, Kalaria RN, et al.
Neuropathologic evidence of endothelial changes in cerebral small vessel
disease. Neurology. 2012;78(3):167–74.
137. Hainsworth AH, Oommen AT, Bridges LR. Endothelial cells and human
cerebral small vessel disease. Brain Pathol. 2015;25(1):44–50.
138. Hassan A, Hunt BJ, O'Sullivan M, Bell R, D'Souza R, Jeffery S, et al.
Homocysteine is a risk factor for cerebral small vessel disease, acting via
endothelial dysfunction. Brain. 2004;127(Pt 1):212–9.
139. Pavlovic AM, Pekmezovic T, Obrenovic R, Novakovic I, Tomic G, Mijajlovic M,
et al. Increased total homocysteine level is associated with clinical status
and severity of white matter changes in symptomatic patients with
subcortical small vessel disease. Clin Neurol Neurosurg. 2011;113(9):711–5.
140. Hainsworth AH, Yeo NE, Weekman EM, Wilcock DM. Homocysteine,
hyperhomocysteinemia and vascular contributions to cognitive impairment
and dementia (VCID). Biochim Biophys Acta. 2016;1862(5):1008–17.
141. Kondziella D, Gothlin M, Fu M, Zetterberg H, Wallin A. B-type natriuretic
peptide plasma levels are elevated in subcortical vascular dementia.
Neuroreport. 2009;20(9):825–7.
142. Mirza SS, de Bruijn RF, Koudstaal PJ, van den Meiracker AH, Franco OH,
Hofman A, et al. The N-terminal pro B-type natriuretic peptide, and risk of
dementia and cognitive decline: a 10-years follow-up study in the general
population. J Neurol Neurosurg Psychiatry. 2016;87(4):356–62.
143. Schneider AL, Rawlings AM, Sharrett AR, Alonso A, Mosley TH, Hoogeveen
RC, et al. High-sensitivity cardiac troponin T and cognitive function and
dementia risk: the atherosclerosis risk in communities study. Eur Heart J.
2014;35(27):1817–24.
144. Pikula A, Boger RH, Beiser AS, Maas R, DeCarli C, Schwedhelm E, et al.
Association of plasma ADMA levels with MRI markers of vascular brain
injury: Framingham offspring study. Stroke. 2009;40(9):2959–64.
145. Tsai NW, Chang YT, Huang CR, Lin YJ, Lin WC, Cheng BC, et al. Association
between oxidative stress and outcome in different subtypes of acute
ischemic stroke. Biomed Res Int. 2014;2014:256879.
146. Wallin A, Ohrfelt A, Bjerke M. Characteristic clinical presentation and CSF biomarker
pattern in cerebral small vessel disease. J Neurol Sci. 2012;322(1–2, 192):–16.
147. Blennow K, Wallin A, Fredman P, Karlsson I, Gottfries CG, Svennerholm L.
Blood–brain barrier disturbance in patients with Alzheimer's disease is
related to vascular factors. Acta Neurol Scand. 1990;81(4):323–6.
148. Frolich L, Kornhuber J, Ihl R, Fritze J, Maurer K, Riederer P. Integrity of the
blood-CSF barrier in dementia of Alzheimer type: CSF/serum ratios of
albumin and IgG. Eur Arch Psychiatry Clin Neurosci. 1991;240(6):363–6.
149. Mroczko B, Groblewska M, Zboch M, Kulczynska A, Koper OM, Szmitkowski
M, et al. Concentrations of matrix metalloproteinases and their tissue
inhibitors in the cerebrospinal fluid of patients with Alzheimer's disease.
J Alzheimers Dis. 2014;40(2):351–7.
150. Horstmann S, Budig L, Gardner H, Koziol J, Deuschle M, Schilling C, et al.
Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in
patients with Alzheimer's disease. Int Psychogeriatr. 2010;22(6):966–72.
151. Peskind ER, Griffin WS, Akama KT, Raskind MA, Van Eldik LJ. Cerebrospinal
fluid S100B is elevated in the earlier stages of Alzheimer's disease.
Neurochem Int. 2001;39(5–6):409–13.
152. Petzold A, Jenkins R, Watt HC, Green AJ, Thompson EJ, Keir G, et al.
Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's
disease. Neurosci Lett. 2003;336(3):167–70.
153. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, et al. YKL-
40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.
Biol Psychiatry. 2010;68(10):903–12.
154. Huang CW, Tsai MH, Chen NC, Chen WH, Lu YT, Lui CC, et al. Clinical
significance of circulating vascular cell adhesion molecule-1 to white matter
disintegrity in Alzheimer's dementia. Thromb Haemost. 2015;114(6):1230–40.
155. Gubandru M, Margina D, Tsitsimpikou C, Goutzourelas N, Tsarouhas K, Ilie M,
et al. Alzheimer's disease treated patients showed different patterns for
oxidative stress and inflammation markers. Food Chem Toxicol. 2013;61:
209–14.
156. Rosenberg GA, Wallin A, Wardlaw JM, Markus HS, Montaner J, Wolfson L, et
al. Consensus statement for diagnosis of subcortical small vessel disease. J
Cereb Blood Flow Metab. 2016;36(1):6–25.
157. Ravid R. The uniqueness of biobanks for neurological and psychiatric
diseases: potentials and pitfalls. Pathobiology. 2014;81(5–6):237–44.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Wallin et al. BMC Neurology  (2017) 17:102 Page 12 of 12
